Company Profile
Neurogene Stock Price, News & Analysis
- Ticker:
- NGNE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
35.60 USD (-1.06%)
Close
Last updated: August 6, 2026
413M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, NGNE closed down 1.06% at $35.60. No new same-company headline was identified in the current news window.
Company overview
Business overview
Neurogene is a gene-therapy company focused on rare neurological diseases. Its story is centered on bringing genetic medicine to severe CNS disorders with very high unmet need.
Geographic Base and Sector Classification
Neurogene is headquartered in the United States and listed on NASDAQ. It sits in gene therapy and neuroscience biotechnology.
Business Model Characteristics
The company depends on clinical progress, manufacturing execution, and the ability to fund a narrow rare-disease pipeline. Investors watch early data and safety closely.
Position Within the Biotechnology Landscape
Neurogene occupies a premium but high-risk gene-therapy niche within biotech. The stock is catalyst-sensitive because the company’s value is tightly linked to a small set of gene-therapy assets.
Future catalysts
Neurogene’s catalysts are NGN-401 and the Rett-syndrome / neurogenetic platform, with each update potentially moving the stock quickly. The company remains early and highly data-dependent.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Neurogene (NGNE)?
Neurogene (NGNE) most recently closed at 35.60 USD, a -1.06% move versus the previous session.
What is the market cap of Neurogene (NGNE)?
Neurogene currently has a market capitalization of 413M USD on BioPharmSignal.
What does Neurogene do?
Neurogene is a gene-therapy company focused on rare neurological diseases. Its story is centered on bringing genetic medicine to severe CNS disorders with very high unmet need.
On which exchange is NGNE stock listed?
Neurogene (NGNE) is associated with NASDAQ, United States, Biopharma.
What is NGN-401?
Neurogene’s catalysts are NGN-401 and the Rett-syndrome / neurogenetic platform, with each update potentially moving the stock quickly.
Which conditions is Neurogene targeting with NGN-401?
Neurogene is associated with genetic disease based on its company overview and current catalyst commentary.
How does Neurogene describe recent progress with NGN-401?
Neurogene’s catalysts are NGN-401 and the Rett-syndrome / neurogenetic platform, with each update potentially moving the stock quickly.
What is Neurogene?
Neurogene is a gene-therapy company focused on rare neurological diseases.